Welcome to our dedicated page for Pavmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. (NASDAQ: PAVM) generates news across medical devices, diagnostics, and digital health, reflecting its role as a diversified, commercial-stage medical technology company. Its news flow often covers developments at the parent company level as well as at its subsidiaries, Lucid Diagnostics Inc. and Veris Health Inc., which focus on cancer prevention diagnostics and digital cancer care.
Investors following PAVM news can expect updates on corporate actions, such as the announced 1-for-30 reverse stock split intended to help the company meet Nasdaq’s minimum bid price requirement and maintain its listing on the Nasdaq Capital Market. Company communications also highlight business updates, quarterly financial results, and information on balance sheet and capital structure decisions, often furnished through press releases and Form 8-K filings.
News related to Lucid Diagnostics, a subsidiary of PAVmed, frequently focuses on the commercialization and clinical performance of the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device. Recent announcements have described large real-world datasets on non-endoscopic esophageal precancer detection, Medicare coverage processes, and participation in medical and investor conferences.
Updates involving Veris Health typically center on the Veris Cancer Care Platform and its deployment in clinical settings. For example, PAVmed and Veris have reported the launch of the commercial phase of a long-term strategic partnership with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, focused on enhancing personalized cancer care for patients undergoing systemic cancer therapy.
This PAVM news page brings together these types of announcements, allowing readers to track financial disclosures, technology and platform milestones, regulatory and reimbursement developments, strategic partnerships, and corporate governance actions over time.
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), announced that its Chairman and CEO, Lishan Aklog, M.D., will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on April 10, 2025, at 11:00 AM EDT. The event will be webcast live and accessible via the Investor Relations Section of Lucid Diagnostics' website. A replay will be available for 30 days post-event. During the conference, company management will also engage in one-on-one meetings with investors.
Lucid Diagnostics (LUCD) has launched the 'Embrace the Future' campaign to highlight its EsoCheck® Esophageal Cell Collection Device with Collect+Protect™ Technology. The campaign will be featured during Esophageal Cancer Awareness Month in April and at the Digestive Disease Week 2025 conference in May.
EsoCheck has demonstrated exceptional performance across nearly 30,000 patients, featuring high patient satisfaction, a perfect safety record, and efficient three-minute procedures in office settings. When combined with Lucid's EsoGuard® Esophageal DNA Test, the technology achieved a remarkable 99% negative predictive value in detecting esophageal precancer.
The company emphasizes EsoCheck's advantages over traditional sponge-on-a-string (SOS) devices, highlighting its precise targeting capabilities and protected sampling approach, contrasting with SOS devices' limitations and history of FDA recalls.
PAVmed (NASDAQ: PAVM) reported its Q4 and full year 2024 financial results, highlighting significant progress across its subsidiaries. Lucid Diagnostics achieved record test volumes with 4,042 EsoGuard tests in Q4 (45% sequential, 84% annual increase) and $1.2 million in revenue. The company secured its first commercial insurance coverage from Highmark Blue Cross Blue Shield.
Veris Health completed a private placement raising $2.4 million at a $35 million pre-money valuation, supplementing a $1.8 million NIH grant. The funds will advance their implantable physiological monitor through FDA clearance.
PAVmed reported Q4 revenues from approximately 125 Veris Cancer Care Platform patients. Operating expenses were $5.2 million, including $0.7 million in stock-based compensation. The company achieved GAAP net income of $1.3 million ($0.12 per diluted share), with non-GAAP adjusted loss of $0.7 million. Cash position stood at $1.2 million, with pro forma cash of $3.6 million including Q1 2025 private placement.
Lucid Diagnostics (NASDAQ: LUCD) reported strong Q4 2024 performance with record 4,042 EsoGuard tests processed, representing a 45% sequential and 84% annual increase. The company recognized $1.2 million in EsoGuard revenue for Q4 2024.
Key achievements include securing over 20 new cash-pay concierge medicine contracts, obtaining first positive commercial insurance coverage from Highmark Blue Cross Blue Shield, and first agreement under state biomarker legislation with BCBS Rhode Island. The company completed a $22 million convertible debt refinancing and $15.3 million common stock financing, extending cash runway.
Financial highlights show Q4 2024 operating expenses of $13.6 million, including $1.2 million in stock-based compensation. GAAP net loss was $11.5 million or $(0.20) per share. Cash position stood at $22.4 million as of December 31, 2024, with pro forma cash of approximately $36.9 million including Q1 2025 financing.
Lucid Diagnostics (LUCD) announced that the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines has updated its recommendations to include esophageal precancer screening. The new guidelines now reference professional society guidelines that recommend non-endoscopic biomarker testing, such as Lucid's EsoGuard® Esophageal DNA Test with EsoCheck® Collection Device, as an acceptable alternative to invasive upper endoscopy for detecting esophageal precancer (Barrett's Esophagus).
This update aligns with the American College of Gastroenterology (ACG) Clinical Guideline and represents a significant step toward recognizing esophageal precancer testing's role in cancer prevention. The company expects this alignment between NCCN Guidelines and gastroenterology society guidelines to positively influence commercial insurance coverage decisions and expand access to EsoGuard testing.
Lucid Diagnostics (Nasdaq: LUCD) announced the acceptance of its ENVET-BE clinical utility study for publication in Gastroenterology & Hepatology, marking the fifth peer-reviewed publication supporting its EsoGuard® Esophageal DNA Test.
The study, examining data from 199 EsoGuard-positive patients who underwent confirmatory upper endoscopy (EGD), demonstrated that EsoGuard significantly improves the detection of esophageal precancer (Barrett's Esophagus or BE). Key findings show:
- 2.4-fold higher diagnostic yield for BE compared to screening EGD alone
- Nearly three-fold higher yield in patients meeting American College of Gastroenterology screening criteria
This research validates EsoGuard as an effective non-invasive triage tool, allowing most at-risk patients to avoid invasive procedures while enhancing the efficiency of endoscopy resource utilization. The study supports ongoing efforts to secure positive commercial insurance coverage policies, following recent success with Highmark Blue Cross Blue Shield.
Lucid Diagnostics (LUCD) has achieved a significant milestone with its first positive commercial insurance coverage for the EsoGuard® Esophageal DNA Test through Highmark Blue Cross Blue Shield in New York state. The regional BCBS plan will cover non-invasive screening of esophageal precancer and cancer for patients meeting established professional society guidelines for testing.
This landmark coverage decision is expected to serve as a precedent for other commercial insurers to follow suit. According to Dr. Lishan Aklog, Lucid's Chairman and CEO, this development validates their clinical evidence base. The company continues to engage with commercial insurers nationwide to expand access to EsoGuard precancer testing.
PAVmed (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company, has announced a business update conference call and webcast scheduled for March 25, 2025, at 8:30 AM ET.
During the call, Chairman and CEO Lishan Aklog, M.D., will provide a business update and overview of company operations and growth strategy. President and CFO Dennis McGrath will discuss fourth quarter 2024 financial results.
- U.S. callers can dial 1-800-836-8184
- International callers can dial 1-646-357-8785
- Conference name: 'PAVmed Business Update'
A 30-day replay will be available in the investor relations section at pavmed.com following the call.
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and PAVmed subsidiary, has scheduled a business update conference call and webcast for March 24, 2025, at 8:30 AM ET.
During the call, Chairman and CEO Lishan Aklog will provide a comprehensive business update, including the company's operations and growth strategy. CFO Dennis McGrath will present the fourth quarter 2024 financial results.
Investors can access the webcast through the company's investor relations website at luciddx.com. For telephone access:
- U.S. callers: 1-800-836-8184
- International callers: 1-646-357-8785
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has completed its previously announced registered direct offering. The company raised $15.3 million in gross proceeds through the sale of 13,939,331 shares of common stock at $1.10 per share.
The net proceeds, after deducting approximately $0.8 million in placement agent fees and other offering expenses, will be used for working capital and general corporate purposes. Canaccord Genuity served as the sole placement agent for the offering.